A Lifetime Partnership With Patients Who Have or May be at Risk of Having Cancer

NCT ID: NCT03617939

Last Updated: 2025-11-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

20000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-09-16

Study Completion Date

2037-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is not a treatment study. The overall objective is to develop an improved standard of care through studying blood, tissue, biological, etc. samples, that patients have allowed researchers to procure.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Oncology Research Information Exchange Network (ORIEN) hopes to establish a unique collection of blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) from thousands of patients with cancer or at risk of having cancer. Their hope is to, over time, facilitate new clinical trials, technology, informatics solutions, and personalized medicine to each cancer patient.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer Risk

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Tissue Repository Blood Samples Biological Samples Surveys Early Detection Risk Assessment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Biospeciman and Data Collection

Patients with cancer or who are at risk of having cancer who have given consent to have blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) collected and stored for the advancement of medicine.

Biospeciman Collection

Intervention Type PROCEDURE

Collection of blood, tissue, and other biological samples.

Survey Assessments

Intervention Type OTHER

Data taken from patient surveys and assessments, including quality of life.

Medical Chart Reviews

Intervention Type OTHER

Data taken directly from the patients' medical charts.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Biospeciman Collection

Collection of blood, tissue, and other biological samples.

Intervention Type PROCEDURE

Survey Assessments

Data taken from patient surveys and assessments, including quality of life.

Intervention Type OTHER

Medical Chart Reviews

Data taken directly from the patients' medical charts.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 18 years of age and older.
2. Diagnosed with cancer, or may be at risk for cancer.
3. Able to understand and sign the TCCP Informed Consent and Research Authorization form directly or through a legally authorized representative (LAR).

Non-English speaking subjects will also be invited to participate in the TCCP study, in accordance with COMIRB's short-form consent use.

Exclusion Criteria

1\. Members of vulnerable populations including neonates (birth to 30 days), children (under age 18), wards of the State, prisoners or those on probation or alternate sentencing, or decisionally challenged (adults or children that are cognitively impaired, incompetent to consent, proxy consent, or consenting in life threatening situations).
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Colorado, Denver

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Virginia Borges, MD

Role: PRINCIPAL_INVESTIGATOR

University of Colorado, Denver

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Colorado Hospital

Aurora, Colorado, United States

Site Status RECRUITING

UCHealth Memorial Hospital Central

Colorado Springs, Colorado, United States

Site Status RECRUITING

UCHealth Memorial Hospital North

Colorado Springs, Colorado, United States

Site Status RECRUITING

Cherry Creek Medical Center

Denver, Colorado, United States

Site Status RECRUITING

UCHealth Poudre Valley Health System

Fort Collins, Colorado, United States

Site Status RECRUITING

Highlands Ranch Medical Center

Highlands Ranch, Colorado, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kyra Anderson

Role: CONTACT

Phone: 303-724-3868

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Virgina Borges, MD

Role: primary

Sara Twombly

Role: primary

Alicia Deschaine

Role: primary

Nathan Ketelhut

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

15-1110.cc

Identifier Type: -

Identifier Source: org_study_id